• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Irenic Welcomes the Appointment of a Shareholder Representative to Theravance Biopharma's Board of Directors

    4/12/23 7:00:00 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TBPH alert in real time by email

    Believes Jim Kelly of Weiss Asset Management Will Bring Important Ownership Mentality to the Boardroom

    Encourages the Board to Continue Taking Concrete Steps to Improve Capital Allocation, Enhance Corporate Governance and Review Strategic Alternatives

    Irenic Capital Management, LP (together with its affiliates, "Irenic" or "we"), a top shareholder of Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance" or the "Company"), today issued the following statement regarding the Company's appointment of Jim Kelly, Managing Director at Weiss Asset Management, to the Board of Directors (the "Board"):

    "Irenic welcomes the appointment of Jim Kelly to the Theravance Board. We respect and admire Jim's investment acumen and thoughtfulness, and believe he brings a much-needed shareholder perspective to the boardroom. We are pleased the Theravance Board added him. The recent steps to increase the extent of the Company's capital return program, modestly refresh the Board and submit a proposal to declassify the Board are steps in the direction of improved capital allocation and good governance.

    We encourage the Board to: (1) Immediately announce a review of strategic alternatives; (2) accelerate the pace of the capital return program; and (3) make real the commitment to declassification by proposing to declassify immediately and by putting the directors up for election this year on a one-year term. Theravance has made progress. This is to be commended. We hope the Board finishes the job."

    About Irenic

    Irenic Capital Management, LP is an investment management firm founded by Adam Katz and Andy Dodge. Based in New York City, Irenic works collaboratively with publicly traded companies to ensure operating activities, capital deployment and management incentives are all aligned to create value for the company and its owners. For more information about Irenic, please visit www.irenicmgmt.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230412005328/en/

    Get the next $TBPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TBPH

    DatePrice TargetRatingAnalyst
    8/6/2024$15.00 → $10.00Outperform → Market Perform
    Leerink Partners
    4/12/2024$21.00Buy
    BTIG Research
    1/8/2024Outperform → In-line
    Evercore ISI
    5/23/2022$12.00Outperform
    SVB Leerink
    3/2/2022$10.00 → $11.00Underweight
    Morgan Stanley
    2/24/2022$8.00 → $12.00Buy
    HC Wainwright & Co.
    11/5/2021$7.00 → $12.00Underweight → Neutral
    JP Morgan
    9/16/2021$14.00 → $10.00Underweight
    Morgan Stanley
    More analyst ratings

    $TBPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Theravance Biopharma downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Theravance Biopharma from Outperform to Market Perform and set a new price target of $10.00 from $15.00 previously

      8/6/24 8:00:45 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Theravance Biopharma with a new price target

      BTIG Research initiated coverage of Theravance Biopharma with a rating of Buy and set a new price target of $21.00

      4/12/24 7:40:50 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theravance Biopharma downgraded by Evercore ISI

      Evercore ISI downgraded Theravance Biopharma from Outperform to In-line

      1/8/24 8:38:16 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TBPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Samaha Eli bought $7,798,440 worth of COM (999,800 units at $7.80) (SEC Form 4)

      4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

      8/9/24 6:02:35 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Samaha Eli bought $13,117,335 worth of COM (1,499,124 units at $8.75) (SEC Form 4)

      4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

      5/3/24 4:19:22 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care